Johnson & Johnson: Tremfya Phase 3b APEX study achieved primary endpoint

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis, compared to placebo. In the Phase 3b APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp score, which includes joint space narrowing and erosion subscores. Data were consistent with the well-established safety profile of Tremfya with no new safety signals identified.